drugset / Trial / NCT01641042

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

NCT01641042

Phase 3 Completed 86 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy subjects.

Timeline

Start
2012-09-10
Primary completion
2014-10-10
Completion
2015-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK134612 Vaccine Intramuscular